• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Around $2.4M Bet On HighPeak Energy? Check Out These 4 Stocks Insiders Are Buying

    1/2/24 9:00:35 AM ET
    $HPK
    $KALV
    $LOVE
    $STCN
    Oil & Gas Production
    Energy
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HPK alert in real time by email

    Although U.S. stocks closed lower on Friday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Lovesac

    • The Trade: The Lovesac Company (NASDAQ:LOVE) Director Andrew R Heyer acquired a total of 9,100 shares an average price of $26.00. To acquire these shares, it cost around $236,594.
    • What’s Happening: Lovesac, last month, posted better-than-expected quarterly sales.
    • What Lovesac Does: The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs.

    KalVista Pharmaceuticals

    • The Trade: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) 10% owner Nimish Shah acquired a total of 519,017 shares at an average price of $12.46. To acquire these shares, it cost around $6.47 million.
    • What’s Happening: KalVista Pharma recently announced publication of first oral factor XIIa data in Frontiers in Pharmacology.
    • What KalVista Pharmaceuticals Does: KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases.

    Don’t forget to check out our premarket coverage here

    HighPeak Energy

    • The Trade: HighPeak Energy, Inc (NASDAQ:HPK) CEO Jack Hightower bought a total of 164,030 shares at an average price of $14.77. To acquire these shares, it cost around $2.42 million.
    • What’s Happening: HighPeak Energy, during November, posted downbeat quarterly earnings.
    • What HighPeak Energy Does: HighPeak Energy Inc is an independent oil and natural gas company focused on the development of unconventional oil and natural gas reserves in primarily Howard County of the Midland Basin.

    Steel Connect

    • The Trade: Steel Connect, Inc. (NASDAQ:STCN) 10% owner WF Asset Corp. bought a total of 8,484 shares at an average price of $9.34. The insider spent around 79,277 to buy those shares.
    • What’s Happening: Steel Connect, last month, reported a decline in quarterly sales.
    • What Steel Connect Does: Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain.

     

    Check This Out: How To Earn $500 A Month From Annaly Capital Management Stock

    Get the next $HPK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HPK
    $KALV
    $LOVE
    $STCN

    CompanyDatePrice TargetRatingAnalyst
    KalVista Pharmaceuticals Inc.
    $KALV
    1/9/2026$32.00 → $35.00Buy
    Needham
    KalVista Pharmaceuticals Inc.
    $KALV
    1/6/2026$28.00 → $32.00Buy
    Needham
    HighPeak Energy Inc.
    $HPK
    10/14/2025$12.00Buy
    Roth Capital
    HighPeak Energy Inc.
    $HPK
    4/7/2025$10.00Underperform
    BofA Securities
    KalVista Pharmaceuticals Inc.
    $KALV
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    KalVista Pharmaceuticals Inc.
    $KALV
    1/7/2025$30.00Buy
    TD Cowen
    KalVista Pharmaceuticals Inc.
    $KALV
    12/18/2024$22.00Buy
    BofA Securities
    The Lovesac Company
    $LOVE
    6/17/2024$36.00 → $38.00Buy
    Maxim Group
    More analyst ratings

    $HPK
    $KALV
    $LOVE
    $STCN
    SEC Filings

    View All

    SEC Form 10-K filed by The Lovesac Company

    10-K - Lovesac Co (0001701758) (Filer)

    4/2/26 7:35:35 AM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by The Lovesac Company

    SCHEDULE 13G - Lovesac Co (0001701758) (Subject)

    3/30/26 5:57:01 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by The Lovesac Company

    SCHEDULE 13G/A - Lovesac Co (0001701758) (Subject)

    3/27/26 10:34:10 AM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    $HPK
    $KALV
    $LOVE
    $STCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Venrock Healthcare Capital Partners Iii, L.P.

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    3/27/26 5:50:10 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fox Mary

    4 - Lovesac Co (0001701758) (Issuer)

    3/20/26 7:40:33 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 4 filed by Nelson Shawn David

    4 - Lovesac Co (0001701758) (Issuer)

    3/20/26 7:39:21 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    $HPK
    $KALV
    $LOVE
    $STCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of KalVista common stock on April 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the first day a closing price is reported following the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case

    4/2/26 4:01:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

    Interim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY® (sebetralstat) for the on-demand treatment of hereditary angioedema (HAE) attacks in children ages 2-11 presented at the 2026 Global Angioedema Leadership Conference. KONFIDENT-KID is the largest pediatric trial ever conducted in HAE. It features a proprietary oral disintegrating tablet (ODT) formulation of sebetralstat in a population that currently relies on burdensome injectable treatments. The s

    3/30/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Lovesac Company Expands Share Repurchase Authorization by $40 Million

    STAMFORD, Conn., March 26, 2026 (GLOBE NEWSWIRE) -- The Lovesac Company (NASDAQ:LOVE) ("Lovesac" or the "Company"), the Designed for Life home and technology brand, today announced that its Board of Directors has authorized the repurchase of up to an additional $40 million of the Company's outstanding common stock, expanding its existing share repurchase program to approximately $54.1 million. Keith Siegner, Executive Vice President and Chief Financial Officer, stated, "We are pleased to announce the expansion of our share repurchase program, reflecting strong confidence in our business outlook. With a healthy balance sheet, access to meaningful liquidity through our credit facility, and

    3/26/26 7:01:00 AM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    $HPK
    $KALV
    $LOVE
    $STCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $35.00 from $32.00 previously

    1/9/26 7:49:25 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    1/6/26 7:58:35 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital resumed coverage on HighPeak Energy with a new price target

    Roth Capital resumed coverage of HighPeak Energy with a rating of Buy and set a new price target of $12.00

    10/14/25 8:50:01 AM ET
    $HPK
    Oil & Gas Production
    Energy

    $HPK
    $KALV
    $LOVE
    $STCN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nelson Shawn David bought $14,410 worth of shares (1,000 units at $14.41), increasing direct ownership by 0.57% to 175,110 units (SEC Form 4)

    4 - Lovesac Co (0001701758) (Issuer)

    10/14/25 4:28:14 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    Director Mclallen Walter Field bought $35,251 worth of shares (1,950 units at $18.08), increasing direct ownership by 5% to 40,000 units (SEC Form 4)

    4 - Lovesac Co (0001701758) (Issuer)

    6/23/25 4:06:17 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    Director Mclallen Walter Field bought $35,415 worth of shares (2,000 units at $17.71), increasing direct ownership by 6% to 38,050 units (SEC Form 4)

    4 - Lovesac Co (0001701758) (Issuer)

    6/20/25 4:11:11 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    $HPK
    $KALV
    $LOVE
    $STCN
    Financials

    Live finance-specific insights

    View All

    The Lovesac Company Reports Fourth Quarter and Fiscal 2026 Financial Results

    Q4 FY26 Net Sales Increased 2.7% to $248.0 million vs. Q4 FY25 FY26 Net Sales Increased 2.4% to $697.1 million vs. FY25Announces New $40 million Share Repurchase Authorization STAMFORD, Conn., March 26, 2026 (GLOBE NEWSWIRE) -- The Lovesac Company (NASDAQ:LOVE) ("Lovesac" or the "Company"), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the fourth quarter and full year fiscal 2026, which ended February 1, 2026. Shawn Nelson, Chief Executive Officer, stated, "Fiscal 2026 was a pivotal year for Lovesac. We made substantial progress on our evolution from a product-driven company into a mu

    3/26/26 7:00:00 AM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update

    $49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary angioedema (HAE) EKTERLY launched in Japan by partner Kaken Pharmaceutical Co., LTD Company to host conference call today at 8:30am ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today reported financial results for the eight months ended December 31, 2025, and provided a corporate update. As previously announced, the Company changed its fiscal year from ending April 30 of each year to ending Dece

    3/25/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company's eight months fiscal year 2025 financial results and provide a corporate update. The live audio webcast will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discov

    3/18/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HPK
    $KALV
    $LOVE
    $STCN
    Leadership Updates

    Live Leadership Updates

    View All

    The Lovesac Company Appoints Wan Ling Martello to Its Board of Directors

    STAMFORD, Conn., Nov. 20, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (NASDAQ:LOVE) ("Lovesac" or the "Company"), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced that Wan Ling Martello has been appointed to the Board of Directors, effective November 20, 2025. Andrew Heyer, Chairman of the Board of Directors, stated, "We are delighted to welcome Wan Ling to our Board of Directors. Her exceptional track record of driving transformational growth at some of the world's most respected consumer and retail companies makes her an invaluable addition to our Board. Her proven expertise in data-driven resource allocati

    11/20/25 7:00:00 AM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    The Lovesac Company Appoints Jacob Pat as Chief Technology and Digital Transformation Officer

    STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (NASDAQ:LOVE) ("Lovesac" or the "Company"), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced the appointment of Jacob Pat as Chief Technology and Digital Transformation Officer effective immediately. Mr. Pat will spearhead Lovesac's enterprise technology and digital transformation agenda as part of the Company's Executive Leadership Team, and report to Mary Fox, President. "Jacob brings an exceptional combination of strategic technology leadership and hands-on digital transformation experience that perfectly aligns with our vision of becomi

    10/21/25 4:05:00 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. "I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY," said Ben Palleiko, Chief Executive Officer of KalVista. "Their respective expertise in operations and human resources will be instrumental as we deliver on our commitment to people living with HAE." "I am excited to join KalVista and collaborate with such a talented team," said Mr. Arif. "This is a pivotal time for EKTERLY, and I am focused on strengthening the operational framework to ensure pe

    10/6/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HPK
    $KALV
    $LOVE
    $STCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by The Lovesac Company

    SC 13G/A - Lovesac Co (0001701758) (Subject)

    11/14/24 4:34:24 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 4:00:06 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 3:57:49 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care